Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET
Company Participants
Juan Sanchez - Vice President, Corporate Communications and Investor Relations
Sharon Mates - Chairman and Chief Executive Officer
Mark Neumann - Executive Vice President and Chief Commercial Officer
Suresh Durgam - Executive Vice President Chief Medical Officer
Larry Hineline - Senior Vice President and Chief Financial Officer
Conference Call Participants
Andrew Tsai - Jefferies
Jessica Fye - JP Morgan
Charles Duncan - Cantor Fitzgerald
Brian Abrahams - RBC Capital Markets
Mike DiFiore - Evercore
Marc Goodman - SVB Securities
Sumant Kulkarni - Canaccord
Jason Gerberry - Bank of America
Karin Jenkins - Goldman Sachs
David Amsellem - Piper Sandler
Operator
Good morning, ladies and gentlemen. And welcome to Intra-Cellular Therapies First Quarter Earnings Call. At this time, all participants are in a listen-only mode [Operator Instructions]. As a reminder, today’s conference call is being recorded.
I’d now like to turn the conference over to Dr. Juan Sanchez, Vice President, Corporate Communications and Investor Relations. Juan?
Juan Sanchez
Good morning, and thank you, all for joining us on the call today. Our earnings press release provides a corporate update and details for the company’s financial results for the first quarter ended in March 31, 2021. This press release is available on our Web site at intracellulartherapries.com. Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer; Mark Neumann, Executive Vice President and Chief Commercial Officer; Dr. Suresh Durgam, Executive Vice President Chief Medical Officer; and Larry Hineline, Senior Vice President and Chief Financial Officer.
As a reminder, during today’s call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety and intended use of the company's product development candidates, our clinical and non-clinical plans, our plans to present or report additional data, the anticipated conduct and results of ongoing and future clinical trials, plans regarding regulatory filings, future research and development, our plans and expectations regarding the commercialization of CAPLYTA, potential impact of the COVID-19 pandemic on our business and possible uses of existing cash and investment resources. These forward-looking statements are based on current information, assumptions and expectations. Those are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the Securities and Exchange Commission, including our quarterly and annual reports. You are cautioned not to place undue reliance on these forward-looking statements, and the company disclaims any obligations to update such statements.